RxDoctor Payments Data

Nouman Siddiqui, MD

Ophthalmology · Raleigh, NCNPI 1144270083

Payments from drug & device makers

$2,105in general payments, 2019–2025

Across 130 payments — averaging $16.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$823
  • Alcon$465
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$199
  • AbbVie$150
  • Glaukos Corporation$137
  • Ocular Therapeutix, Inc.$89
  • plus $243 from 7 others

What the payments were for

  • Food & beverage$2,08499%
  • Education$211%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,105 in reported general payments places this provider in the 55th percentile of 588 ophthalmology providers in North Carolina.

See all ophthalmology providers in North Carolina

Medicare billing

Part B allowed, 2024
$216,066
Medicare patients
568
Services billed
2,367

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine205$161,695
LumiganBimatoprost204$96,285
RhopressaNetarsudil Mesylate100$48,069
Alphagan PBrimonidine Tartrate119$41,706
Brinzolamide172$32,164
XiidraLifitegrast34$30,659
CombiganBrimonidine Tartrate/Timolol49$23,375
Latanoprost2,363$22,628
VyzultaLatanoprostene Bunod64$21,985
Cyclosporine57$21,498
SimbrinzaBrinzolamide/Brimonidine Tart57$19,812
AzoptBrinzolamide33$17,452
Travoprost97$15,654
Brimonidine Tartrate607$14,408
Dorzolamide-TimololDorzolamide/Timolol/Pf75$13,271

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Alphagan P, Combigan$150$323,060577 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta, Miebo$823$63,738109 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$19$53,306116 claims
AlconSimbrinza, Azopt$465$37,26490 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$199$1,91116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 588 ophthalmology providers in North Carolina.

Other ophthalmology in Raleigh

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →